![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SP Welch and DL Stevens
Department of Pharmacology and Toxicology, Medical College of Virginia, Richmond.
The antinociceptive effects of various cannabinoids, alone and in combination with opiates, were evaluated in antinociceptive tests in mice. The cannabinoids tested produce marked antinociceptive effects after i.t. administration to mice. The rank order of potency for the drugs using the tail-flick test was levonantradol greater than CP- 55,940 = CP-56,667 greater than 11-hydroxy-delta 9-THC greater than delta 9-THC greater than delta 8-THC; dextronantradol was inactive at a dose of 25 micrograms/mouse. Respective ED50 values in the tail-flick test were 0.4, 12.3, 4.2, 15, 45 and 72 micrograms/mouse. Although pretreatment with morphine somewhat enhanced the effects of delta 9- THC, pretreatment of the mice with naloxone (1 mg/kg s.c. or 1 micrograms/mouse i.t.) failed to block the antinociceptive effects of the cannabinoids, indicating that the cannabinoid-induced antinociception does not occur due to direct interaction with the opiate receptor. Pretreatment of mice with 3.13 micrograms/mouse and 6.25 micrograms/mouse of delta 9-THC shifted the ED50 of morphine to 0.15 and 0.05 micrograms/mouse, respectively (a 4-and a 12-fold shift). The shifts in the dose-response curve of the morphine were parallel. Naloxone administration (1 mg/kg s.c.) completely blocked the antinociceptive effects of the combination of 6.25 micrograms of delta 9-THC with morphine. The AD50 for naloxone blockade of the drug combination was 0.24 (0.06-0.94) mg/kg s.c. and the pA2 was 7.7 (6.7- 8.9). The pA2 for naloxone blockade of the dimethylsulfoxide-morphine combination was 6.9 (5.7-8.1).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  S. Kang, C. H. Kim, H. Lee, D. Y. Kim, J. I. Han, R. K. Chung, and G. Y. Lee Antinociceptive Synergy Between the Cannabinoid Receptor Agonist WIN 55,212-2 and Bupivacaine in the Rat Formalin Test Anesth. Analg., March 1, 2007; 104(3): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Iversen Cannabis and the brain Brain, June 1, 2003; 126(6): 1252 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Cichewicz and E. A. McCarthy Antinociceptive Synergy between Delta 9-Tetrahydrocannabinol and Opioids after Oral Administration J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Navarro, M. R. A. Carrera, W. Fratta, O. Valverde, G. Cossu, L. Fattore, J. A. Chowen, R. Gomez, I. del Arco, M. A. Villanua, et al. Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration J. Neurosci., July 15, 2001; 21(14): 5344 - 5350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Cichewicz, V. L. Haller, and S. P. Welch Changes in Opioid and Cannabinoid Receptor Protein following Short-Term Combination Treatment with {Delta}9-Tetrahydrocannabinol and Morphine J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 121 - 127. [Abstract] [Full Text]
|
|
|
|
|
|
O. Valverde, R. Maldonado, E. Valjent, A. M. Zimmer, and A. Zimmer Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice J. Neurosci., December 15, 2000; 20(24): 9284 - 9289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Hampson, J. Mu, and S. A. Deadwyler Cannabinoid and Kappa Opioid Receptors Reduce Potassium K Current via Activation of Gs Proteins in Cultured Hippocampal Neurons J Neurophysiol, November 1, 2000; 84(5): 2356 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Cichewicz, Z. L. Martin, F. L. Smith, and S. P. Welch Enhancement of µ Opioid Antinociception by Oral Delta 9-Tetrahydrocannabinol: Dose-Response Analysis and Receptor Identification J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 859 - 867. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Ledent, O. Valverde, G. Cossu, F. Petitet, J. Aubert, F. Beslot, G. A. Böhme, A. Imperato, T. Pedrazzini, B. P. Roques, et al. Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB1 Receptor Knockout Mice Science, January 15, 1999; 283(5400): 401 - 404. [Abstract] [Full Text]
|
|
|
|
|
|
S. P. Welch, J. W. Huffman, and J. Lowe Differential Blockade of the Antinociceptive Effects of Centrally Administered Cannabinoids by SR141716A J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1301 - 1308. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Vivian, S. Kishioka, E. R. Butelman, J. Broadbear, K. O. Lee, and J. H. Woods Analgesic, Respiratory and Heart Rate Effects of Cannabinoid and Opioid Agonists in Rhesus Monkeys: Antagonist Effects of SR 141716A J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 697 - 703. [Abstract] [Full Text]
|
|
|
|
|
|
G. Pugh Jr., D. J. Mason Jr., V. Combs, and S. P. Welch Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 730 - 737. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
